VCEL (Vericel Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by VCEL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | KEVIN F MCLAUGHLIN | Director | MIXED | — | — |
| 2026-08-05 | Michael Halpin | Chief Operating Officer | MIXED | — | — |
| 2026-07-31 | JONATHAN SIEGAL | Principal Accounting Officer | MIXED | — | — |
| 2026-06-22 | Sean C. Flynn | Chief Legal Officer | MIXED | — | — |
| 2026-06-22 | Michael Halpin | Chief Operating Officer | MIXED | — | — |
| 2026-06-04 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | — |
| 2026-05-15 | KEVIN F MCLAUGHLIN | Director | MIXED | — | — |
| 2026-05-13 | Paul K Wotton | Director | Sell | — | — |
| 2026-05-08 | Joseph Anthony Mara Jr | Chief Financial Officer | Sell | — | — |
| 2026-05-08 | JONATHAN SIEGAL | Principal Accounting Officer | Sell | — | — |
| 2026-05-01 | Paul K Wotton | Director | M | — | — |
| 2026-05-01 | KEVIN F MCLAUGHLIN | Director | M | — | — |
| 2026-05-01 | Heidi Hagen | Director | M | — | — |
| 2026-05-01 | Alan L Rubino | Director | M | — | — |
| 2026-05-01 | LISA WRIGHT | Director | M | — | — |
| 2026-05-01 | ROBERT L MD ZERBE | Director | M | — | — |
| 2026-04-06 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | — |
| 2026-03-27 | Alan L Rubino | Director | M | — | — |
| 2026-03-25 | Heidi Hagen | Director | MIXED | — | — |
| 2026-03-04 | Michael Halpin | Chief Operating Officer | Sell | — | — |
| 2026-03-04 | Sean C. Flynn | Chief Legal Officer | MIXED | — | — |
| 2026-02-26 | Joseph Anthony Mara Jr | Chief Financial Officer | MIXED | — | — |
| 2026-02-26 | Sean C. Flynn | Chief Legal Officer | MIXED | — | — |
| 2026-02-26 | Michael Halpin | Chief Operating Officer | MIXED | — | — |
| 2026-02-26 | Dominick Colangelo | President and CEO | MIXED | — | — |
| 2026-02-26 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | — |
| 2026-02-26 | JONATHAN SIEGAL | Principal Accounting Officer | MIXED | — | — |
| 2026-02-20 | Michael Halpin | Chief Operating Officer | MIXED | — | — |
| 2026-02-20 | Sean C. Flynn | Chief Legal Officer | MIXED | — | — |
| 2026-02-20 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | — |
| 2026-02-20 | Joseph Anthony Mara Jr | Chief Financial Officer | MIXED | — | — |
| 2026-02-20 | Dominick Colangelo | President and CEO | MIXED | — | — |
| 2026-02-20 | JONATHAN SIEGAL | Principal Accounting Officer | MIXED | — | — |
| 2026-02-13 | KEVIN F MCLAUGHLIN | Director | MIXED | — | — |
| 2026-01-09 | Michael Halpin | Chief Operating Officer | MIXED | — | — |
| 2025-12-12 | Karen Mahoney | Chief Human Resources Officer | MIXED | — | — |
| 2025-12-04 | Paul K Wotton | Director | Sell | — | — |
| 2025-12-04 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | — |
| 2025-11-13 | Michael Halpin | Chief Operating Officer | MIXED | — | — |
| 2025-11-12 | KEVIN F MCLAUGHLIN | Director | MIXED | — | — |
| 2025-11-10 | Michael Halpin | Chief Operating Officer | MIXED | — | — |
| 2025-10-02 | JONATHAN SIEGAL | Principal Accounting Officer | MIXED | — | — |
| 2025-09-03 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | — |
| 2025-08-08 | KEVIN F MCLAUGHLIN | Director | MIXED | — | — |
| 2025-06-04 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | — |
| 2025-05-16 | Dominick Colangelo | President and CEO | MIXED | — | — |
| 2025-05-09 | KEVIN F MCLAUGHLIN | Director | MIXED | — | — |
| 2025-05-02 | Karen Mahoney | Chief Human Resources Officer | A | — | — |
| 2025-05-02 | Heidi Hagen | Director | M | — | — |
| 2025-05-02 | ROBERT L MD ZERBE | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,232,940 | — |
| — | President and CEO | 303,020 | — |
| — | CFO and VP, Corp. Development | 253,865 | — |
| — | Chief Medical Officer | 80,128 | — |
| — | Director | 64,234 | — |
| — | Director | 35,050 | — |
| — | Director | 32,995 | — |
| — | Chief Operating Officer | 32,753 | — |
| — | Chief Financial Officer | 21,009 | — |
| — | Director | 18,802 | — |
| — | Director | 18,300 | — |
| — | Chief Legal Officer | 16,647 | — |
| — | Director | 15,851 | — |
| — | Chief Operating Officer | 14,710 | — |
| — | Director | 11,000 | — |
| — | Chief Human Resources Officer | 2,625 | — |
| — | Principal Accounting Officer | 1,578 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VCEL quote page; the site-wide leaderboard is on the insider transactions hub.